This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Talwar R , Friel B , Mittal S , Xia L , Fonshell C , Danella J , Jacobs B , Lanchoney T , Raman J , Tomaszewski J , Trabulsi E , Reese A , Singer EA , Ginzburg S , Smaldone M , Uzzo R , Mucksavage P , Guzzo TJ , Lee DJ
Concordance of confirmatory prostate biopsy in active surveillance with national guidelines: An analysis from the multi-institutional PURC cohort
Urol Oncol. 2020 Nov;38(11) :846 e17-846 e22
PMID: 32739228 URL: https://www.ncbi.nlm.nih.gov/pubmed/32739228
AbstractPURPOSE: National Comprehensive Cancer Network (NCCN) guidelines recommend confirmatory biopsy within 12 months of active surveillance (AS) enrollment. With <10 cores on initial biopsy, re-biopsy should occur within 6 months. Our objective was to determine if patients on AS within practices in the Pennsylvania Urologic Regional Collaborative (PURC) receive guideline concordant confirmatory biopsies. MATERIALS AND METHODS: Within PURC, a prospective collaborative of diverse urology practices in Pennsylvania and New Jersey, we identified men enrolled in AS after first biopsy, analyzing time to re-biopsy and factors associated with various intervals of re-biopsy. RESULTS: In total, 1,047 patients were enrolled in AS for a minimum of 12 months after initial biopsy. Four hundred seventy-seven (45%) underwent second biopsy at 1 of the 9 PURC practices. The number of patients undergoing re-biopsy within 6 months, 6 to 12 months, 12 to 18 months, and >18 months was 71 (14%), 218 (45.7%), 134 (28%), and 54 (11%), respectively. Sixty percent underwent confirmatory biopsy within 12 months. On multivariate analysis, re-biopsy interval was associated with number of positive cores, perineural invasion, and practice ID (all P < 0.05). Adjusted multivariable regression did not identify factors predictive of re-biopsy interval. CONCLUSION: Of patients who underwent confirmatory biopsy at PURC practices, 60.5% were within 12 months per NCCN guidelines. This suggests area for improvement in guideline adherence after enrollment in AS. All practices that offer AS should periodically perform similar analyses to monitor their performance. In an era of value-based care, adherence to guideline based active surveillance practices may eventually comprise national quality metrics affecting provider reimbursement.
Notes1873-2496 Talwar, Ruchika Friel, Brian Mittal, Sameer Xia, Leilei Fonshell, Claudette Danella, John Jacobs, Bruce Lanchoney, Thomas Raman, Jay Tomaszewski, Jeffrey Trabulsi, Edouard Reese, Adam Singer, Eric A Ginzburg, Serge Smaldone, Marc Uzzo, Robert Mucksavage, Phillip Guzzo, Thomas J Lee, Daniel J Journal Article United States Urol Oncol. 2020 Jul 29:S1078-1439(20)30330-6. doi: 10.1016/j.urolonc.2020.07.008.